Costs and quality of life of multiple sclerosis in Spain

European Journal of Health Economics

Volumn 7, Issue 2 SUPPL., 2006, Pages

  Kobelt, G ^a,b   Berg, J ^c   Lindgren, P ^c   Izquierdo, G ^d   Sanchez Solino O ^e   Perez Miranda J ^e   Casado, M A ^f  

^a LUND UNIVERSITY   (Sweden)

^b European Health Economics ^*  (France)

^c STOCKHOLM HEALTH ECONOMICS   (Sweden)

^d HOSPITAL UNIVERSITARIO VIRGEN MACARENA   (Spain)

^e Medical Department   (Spain)

^f Pharmacoeconomics and Outcomes Research Iberia (PORIB)   (Spain)

Author keywords

Costs; Multiple sclerosis; Quality of life; Spain; Utility

Indexed keywords

ABSENTEEISM; ADULT; AGED; AMBULATORY CARE; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE CLASSIFICATION; DISEASE COURSE; DISEASE SEVERITY; EXPANDED DISABILITY STATUS SCALE; FEMALE; FUNCTIONAL STATUS; HEALTH CARE COST; HEALTH CARE ORGANIZATION; HEALTH CARE UTILIZATION; HEALTH SERVICE; HEALTH SURVEY; HOSPITALIZATION; HUMAN; INVESTMENT; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; PATIENT CARE; POPULATION RESEARCH; PRIORITY JOURNAL; PRODUCTIVITY; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; QUESTIONNAIRE; RELAPSE; RESOURCE ALLOCATION; SPAIN;

ABSENTEEISM; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; COST OF ILLNESS; COSTS AND COST ANALYSIS; CROSS-SECTIONAL STUDIES; EFFICIENCY; FEMALE; HEALTH EXPENDITURES; HEALTH SERVICES; HUMANS; MALE; MIDDLE AGED; MODELS, ECONOMETRIC; MULTIPLE SCLEROSIS; QUALITY OF LIFE; QUALITY-ADJUSTED LIFE YEARS; RECURRENCE; SEVERITY OF ILLNESS INDEX; SPAIN;

EID: 33847256825     PISSN: 16187598     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10198-006-0381-y     Document Type: Article

References (19)

1. Kobelt, G, Berg J, Lindgren P et al. (2006) Costs and quality of life of multiple sclerosis in Europe. J Neurol Neurosurg Psychatry. Online publication, May 11
2. Casquero P, Villoslada P, Montalban X, Torrent M (2001) Frequency of multiple sclerosis in Menorca, Balearic Islands, Spain. Neuroepidemiology 20: 129-133
3. Modrego Pardo P, Pina Latorre M, Lopez A, Errea J (1997) Prevalence of multiple sclerosis in the province of Teruel, Spain. J Neurol 244: 182-185
4. Benito-Leon J, Martin E, Vela L et al. (1998) Multiple sclerosis in Mostoles, central Spain. Acta Neurol Scand 98: 238-242
5. Aladro Y, Alemany M, Perez-Vieitez M et al. (2005) Prevalence and incidence of multiple sclerosis in Las Palmas, Canary Islands, Spain. Neuroepidemiology 24: 70-75
6. Rosati G (2001) The prevalence of multiple sclerosis in the world: an update. Neurol Sci 22: 117-139
7. Pugliatti M, Rosati R, Carton H et al. (2006) The prevalence and incidence of multiple sclerosis in Europe. Eur J Neurology 13: 1-23
8. Kurtzke J (1983) Rating neurological impairment in multiple sclerosis and expanded disability status scale (EDSS). Neurology 33: 1444-1452
9. The EuroQol Group (1990) EuroQol - a new facility for the measurement of health-related quality of life. Health Policy 16: 199-208
10. Dolan P (1995) A social tariff for EuroQol: results from a UK general population survey. Centre for Health Economics, University of York: York
11. The EuroQol Group (2004) Measuring self-reported population health: an international perspective based on EQ-5D. Szende A, Williams A (eds) Hungary: Spring Med Publishing
12. Henriksson F, Fredrikson S, Jönsson B (2000) Costs, quality of life and disease severity in multiple sclerosis - a cross-sectional study in Sweden. SSE/EFI Working Paper Series in Economics and Finance No. 361. Stockholm School of Economics; Stockholm, Sweden
13. Kobelt, G, Lindgren P, Smala A, Jönsson B, Group Gms (2001) Costs and quality of life in multiple sclerosis. A cross-sectional observational study in Germany. Eur J Health Econ 2: 60-68
14. Kobelt G, Lindgren P, Parkin D, Jönsson B (2000) Costs and quality of life in multiple sclerosis. A cross-sectional observational study in the United Kingdom. SEE/EFI Working Paper Series in Economics and Finance No. 399. Stockholm School of Economics; Stockholm, Sweden
15. Eichler H, Kong S, Gerth W et al. (2004) Use of cost-effectiveness analysis in health care resource allocation decision-making: how are cost-effectiveness thresholds expected to emerge? Value Health 7: 518-528
16. Hohol M, Orav E, Weiner H (1995) Disease steps in multiple sclerosis: a simple approach to evaluate disease progression. Neurology 45: 251-255
17. Kobelt G, Jönsson L, Fredrikson S (2003) A new disease model to estimate the cost of disease progression for different types of MS and different subgroups of patients. Eur J Health Econ 4: 50-59
18. Rubio-Terres C, Aristegui-Ruiz I, Medina-Redondo F, Izquirdo-Ayuso G (2003) Analisis cost-utilidad del tratamiento de la esclerosis ultiple remitente-recidivante con aceto de glatiramero o interferon beta en Espagna. Farmacia Hospitalaria 27: 159-165
19. Morales-Gonzalez J, Benito-Leon J, Rivera-Navarro J, Mitchell A (2000) A systematic approach to analyse health-related quality of life in multiple sclerosis: the GEDMA study. Mult Scler 10: 47-54